Satish Garg
Concepts (669)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypoglycemic Agents | 107 | 2026 | 1388 | 17.560 |
Why?
| | Diabetes Mellitus, Type 1 | 158 | 2026 | 3910 | 16.650 |
Why?
| | Blood Glucose | 122 | 2026 | 2326 | 12.900 |
Why?
| | Blood Glucose Self-Monitoring | 73 | 2026 | 699 | 11.690 |
Why?
| | Insulin | 89 | 2026 | 2502 | 10.340 |
Why?
| | Diabetes Mellitus, Type 2 | 59 | 2025 | 2573 | 8.640 |
Why?
| | Diabetes Mellitus | 32 | 2024 | 1076 | 7.330 |
Why?
| | Hypoglycemia | 53 | 2026 | 479 | 6.550 |
Why?
| | Insulin Infusion Systems | 42 | 2026 | 477 | 5.910 |
Why?
| | Monitoring, Ambulatory | 17 | 2017 | 89 | 4.050 |
Why?
| | Myometrium | 9 | 2021 | 38 | 3.940 |
Why?
| | Buffaloes | 11 | 2021 | 12 | 3.930 |
Why?
| | Diabetic Ketoacidosis | 12 | 2024 | 210 | 3.360 |
Why?
| | Spermatozoa | 8 | 2024 | 107 | 3.320 |
Why?
| | Periodicals as Topic | 7 | 2020 | 206 | 3.010 |
Why?
| | Biosimilar Pharmaceuticals | 6 | 2020 | 28 | 2.940 |
Why?
| | Insulin Glargine | 25 | 2022 | 88 | 2.870 |
Why?
| | Hyperglycemia | 17 | 2022 | 374 | 2.840 |
Why?
| | Glycosides | 10 | 2024 | 43 | 2.780 |
Why?
| | Overweight | 6 | 2026 | 606 | 2.760 |
Why?
| | Uterine Contraction | 8 | 2021 | 17 | 2.650 |
Why?
| | Pregnancy in Diabetics | 13 | 2023 | 121 | 2.550 |
Why?
| | Sperm Motility | 7 | 2024 | 35 | 2.450 |
Why?
| | Dog Diseases | 4 | 2021 | 70 | 2.350 |
Why?
| | Insulin Lispro | 14 | 2022 | 42 | 2.320 |
Why?
| | Insulin Aspart | 9 | 2020 | 30 | 2.260 |
Why?
| | Glucagon-Like Peptides | 5 | 2026 | 70 | 2.140 |
Why?
| | Biomedical Technology | 5 | 2023 | 49 | 2.090 |
Why?
| | Mercury | 4 | 2025 | 40 | 2.070 |
Why?
| | Insulin, Long-Acting | 21 | 2022 | 65 | 2.040 |
Why?
| | Humans | 217 | 2026 | 144671 | 2.010 |
Why?
| | Cytokines | 7 | 2021 | 2045 | 1.970 |
Why?
| | Pancreas, Artificial | 5 | 2024 | 97 | 1.950 |
Why?
| | Calcium | 9 | 2024 | 1182 | 1.850 |
Why?
| | Lead | 3 | 2024 | 70 | 1.680 |
Why?
| | Sperm Capacitation | 6 | 2021 | 12 | 1.560 |
Why?
| | Plant Extracts | 5 | 2019 | 188 | 1.550 |
Why?
| | Obesity | 6 | 2026 | 3070 | 1.530 |
Why?
| | Adult | 93 | 2026 | 40489 | 1.490 |
Why?
| | Female | 124 | 2026 | 78304 | 1.460 |
Why?
| | Antioxidants | 5 | 2020 | 546 | 1.440 |
Why?
| | Telemedicine | 6 | 2021 | 957 | 1.440 |
Why?
| | Male | 108 | 2026 | 72431 | 1.400 |
Why?
| | Sepsis | 3 | 2023 | 643 | 1.300 |
Why?
| | Theileriasis | 2 | 2020 | 2 | 1.290 |
Why?
| | Insulins | 2 | 2024 | 38 | 1.290 |
Why?
| | Cattle | 9 | 2024 | 975 | 1.260 |
Why?
| | Animals | 52 | 2025 | 37948 | 1.240 |
Why?
| | Mite Infestations | 2 | 2020 | 9 | 1.220 |
Why?
| | Drug Therapy, Combination | 15 | 2026 | 1044 | 1.220 |
Why?
| | Injections, Subcutaneous | 11 | 2021 | 168 | 1.220 |
Why?
| | Middle Aged | 61 | 2026 | 35971 | 1.190 |
Why?
| | rho-Associated Kinases | 3 | 2021 | 82 | 1.160 |
Why?
| | Calcium Signaling | 3 | 2021 | 243 | 1.150 |
Why?
| | Vasoconstriction | 2 | 2022 | 216 | 1.150 |
Why?
| | Postprandial Period | 5 | 2020 | 114 | 1.110 |
Why?
| | Trace Elements | 2 | 2020 | 52 | 1.080 |
Why?
| | Pre-Eclampsia | 10 | 2023 | 203 | 1.080 |
Why?
| | Diabetes Complications | 5 | 2020 | 223 | 1.050 |
Why?
| | Non-alcoholic Fatty Liver Disease | 2 | 2021 | 265 | 1.040 |
Why?
| | Trypanosomiasis | 2 | 2017 | 5 | 1.020 |
Why?
| | 3-Hydroxybutyric Acid | 3 | 2024 | 17 | 1.020 |
Why?
| | Insulin, Isophane | 6 | 2017 | 22 | 1.000 |
Why?
| | Dermatitis, Atopic | 2 | 2021 | 323 | 0.990 |
Why?
| | Rats, Wistar | 11 | 2020 | 449 | 0.980 |
Why?
| | Pandemics | 5 | 2022 | 1700 | 0.960 |
Why?
| | Protein Kinase C | 2 | 2018 | 250 | 0.950 |
Why?
| | Drugs, Investigational | 2 | 2017 | 31 | 0.950 |
Why?
| | Glucagon-Like Peptide 1 | 4 | 2025 | 146 | 0.910 |
Why?
| | Histamine | 2 | 2017 | 53 | 0.910 |
Why?
| | Acrosome Reaction | 2 | 2024 | 3 | 0.890 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 387 | 0.870 |
Why?
| | Coronavirus Infections | 2 | 2020 | 381 | 0.870 |
Why?
| | Acrosome | 1 | 2024 | 6 | 0.850 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 3 | 2013 | 46 | 0.850 |
Why?
| | Uterus | 6 | 2021 | 224 | 0.820 |
Why?
| | Monitoring, Physiologic | 6 | 2023 | 288 | 0.800 |
Why?
| | Biomedical Research | 8 | 2017 | 712 | 0.790 |
Why?
| | Treatment Outcome | 23 | 2026 | 11735 | 0.780 |
Why?
| | Diabetic Nephropathies | 2 | 2025 | 318 | 0.780 |
Why?
| | Reproducibility of Results | 14 | 2025 | 3414 | 0.770 |
Why?
| | Weight Loss | 4 | 2025 | 839 | 0.750 |
Why?
| | Angiotensin II | 1 | 2023 | 95 | 0.750 |
Why?
| | Spleen | 3 | 2020 | 510 | 0.730 |
Why?
| | Cross-Over Studies | 10 | 2020 | 605 | 0.730 |
Why?
| | Dinoprost | 2 | 2021 | 49 | 0.730 |
Why?
| | Receptor, Notch3 | 1 | 2022 | 8 | 0.720 |
Why?
| | Sulfones | 2 | 2020 | 127 | 0.710 |
Why?
| | Benzamides | 2 | 2020 | 224 | 0.700 |
Why?
| | Administration, Inhalation | 4 | 2018 | 570 | 0.690 |
Why?
| | Aorta | 2 | 2022 | 427 | 0.690 |
Why?
| | Nifedipine | 6 | 2021 | 27 | 0.680 |
Why?
| | Young Adult | 28 | 2026 | 14122 | 0.680 |
Why?
| | Intermediate Filament Proteins | 1 | 2021 | 57 | 0.680 |
Why?
| | Dose-Response Relationship, Drug | 14 | 2020 | 2019 | 0.670 |
Why?
| | Glucose | 6 | 2024 | 1033 | 0.670 |
Why?
| | Type C Phospholipases | 2 | 2018 | 69 | 0.670 |
Why?
| | Signal Transduction | 6 | 2024 | 5185 | 0.670 |
Why?
| | TRPC Cation Channels | 2 | 2021 | 14 | 0.670 |
Why?
| | Arterial Pressure | 1 | 2022 | 133 | 0.670 |
Why?
| | Insulin Antibodies | 2 | 2020 | 103 | 0.670 |
Why?
| | Pregnancy | 23 | 2023 | 7122 | 0.660 |
Why?
| | Trypanosoma | 2 | 2017 | 8 | 0.660 |
Why?
| | Mitochondrial Membranes | 1 | 2021 | 40 | 0.650 |
Why?
| | Biopolymers | 1 | 2020 | 35 | 0.650 |
Why?
| | Dogs | 5 | 2021 | 438 | 0.650 |
Why?
| | Registries | 8 | 2025 | 2392 | 0.650 |
Why?
| | Endometritis | 2 | 2017 | 4 | 0.650 |
Why?
| | Calcium Channel Blockers | 6 | 2021 | 165 | 0.650 |
Why?
| | Theileria annulata | 1 | 2020 | 1 | 0.650 |
Why?
| | Chitosan | 1 | 2020 | 39 | 0.640 |
Why?
| | Protein Precursors | 1 | 2021 | 136 | 0.640 |
Why?
| | Copper Sulfate | 1 | 2020 | 8 | 0.640 |
Why?
| | Diabetic Angiopathies | 6 | 2013 | 262 | 0.640 |
Why?
| | Gelatin | 1 | 2020 | 56 | 0.640 |
Why?
| | Exophthalmos | 1 | 2020 | 18 | 0.630 |
Why?
| | Sodium-Glucose Transporter 1 | 2 | 2017 | 11 | 0.630 |
Why?
| | Betacoronavirus | 2 | 2020 | 286 | 0.630 |
Why?
| | Calcium Channels | 2 | 2018 | 155 | 0.630 |
Why?
| | Cattle Diseases | 1 | 2020 | 26 | 0.630 |
Why?
| | Sulfonylurea Compounds | 2 | 2018 | 51 | 0.630 |
Why?
| | Mutagens | 1 | 2020 | 27 | 0.630 |
Why?
| | Selenium | 1 | 2020 | 49 | 0.630 |
Why?
| | Peste-des-petits-ruminants virus | 1 | 2019 | 1 | 0.620 |
Why?
| | Polyalthia | 1 | 2019 | 1 | 0.620 |
Why?
| | Oleic Acid | 1 | 2020 | 42 | 0.610 |
Why?
| | Aged | 29 | 2026 | 25955 | 0.610 |
Why?
| | Newcastle disease virus | 1 | 2019 | 18 | 0.610 |
Why?
| | Infusions, Subcutaneous | 4 | 2016 | 24 | 0.610 |
Why?
| | Patient Education as Topic | 6 | 2020 | 771 | 0.610 |
Why?
| | Mites | 1 | 2019 | 8 | 0.610 |
Why?
| | Isoproterenol | 1 | 2020 | 96 | 0.600 |
Why?
| | Down-Regulation | 1 | 2022 | 616 | 0.600 |
Why?
| | Peroxidase | 2 | 2017 | 167 | 0.600 |
Why?
| | Potassium Channels | 1 | 2020 | 145 | 0.580 |
Why?
| | Toll-Like Receptors | 1 | 2020 | 193 | 0.570 |
Why?
| | Uterine Artery | 1 | 2019 | 74 | 0.570 |
Why?
| | Cardiovascular Diseases | 3 | 2025 | 2172 | 0.570 |
Why?
| | Oxidative Stress | 4 | 2020 | 1338 | 0.570 |
Why?
| | Adolescent | 33 | 2026 | 22409 | 0.560 |
Why?
| | Endocannabinoids | 2 | 2019 | 57 | 0.560 |
Why?
| | Mercuric Chloride | 1 | 2018 | 2 | 0.560 |
Why?
| | GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2018 | 19 | 0.550 |
Why?
| | Biosensing Techniques | 2 | 2018 | 140 | 0.540 |
Why?
| | Voltage-Gated Sodium Channels | 1 | 2017 | 5 | 0.540 |
Why?
| | Tocolysis | 1 | 2017 | 4 | 0.540 |
Why?
| | Wound Healing | 1 | 2020 | 352 | 0.540 |
Why?
| | Eucalyptus | 1 | 2017 | 5 | 0.540 |
Why?
| | Ethanolamines | 1 | 2017 | 14 | 0.540 |
Why?
| | Vasodilation | 2 | 2019 | 520 | 0.530 |
Why?
| | Potassium Channels, Voltage-Gated | 1 | 2018 | 55 | 0.530 |
Why?
| | Weight Gain | 6 | 2024 | 557 | 0.530 |
Why?
| | Oxytocin | 2 | 2016 | 51 | 0.530 |
Why?
| | KATP Channels | 1 | 2017 | 23 | 0.530 |
Why?
| | Interleukins | 1 | 2019 | 248 | 0.530 |
Why?
| | Norepinephrine | 1 | 2018 | 196 | 0.520 |
Why?
| | Immunoglobulin E | 1 | 2019 | 315 | 0.520 |
Why?
| | Double-Blind Method | 9 | 2024 | 2033 | 0.520 |
Why?
| | Hydrogen Sulfide | 1 | 2017 | 48 | 0.510 |
Why?
| | Self Care | 4 | 2013 | 389 | 0.510 |
Why?
| | Endothelium, Vascular | 3 | 2019 | 949 | 0.510 |
Why?
| | NAV1.8 Voltage-Gated Sodium Channel | 1 | 2016 | 3 | 0.510 |
Why?
| | Disposable Equipment | 3 | 2026 | 24 | 0.500 |
Why?
| | Syringes | 3 | 2013 | 49 | 0.500 |
Why?
| | Cadmium | 1 | 2017 | 68 | 0.500 |
Why?
| | Therapies, Investigational | 1 | 2017 | 18 | 0.500 |
Why?
| | Inflammation Mediators | 1 | 2020 | 503 | 0.500 |
Why?
| | Reactive Oxygen Species | 1 | 2020 | 601 | 0.500 |
Why?
| | Coinfection | 1 | 2018 | 141 | 0.500 |
Why?
| | Muscle Relaxation | 1 | 2016 | 28 | 0.490 |
Why?
| | Cholinesterases | 1 | 2016 | 9 | 0.490 |
Why?
| | Mitochondria | 2 | 2021 | 984 | 0.480 |
Why?
| | Minerals | 1 | 2016 | 48 | 0.480 |
Why?
| | Hospitalization | 2 | 2024 | 2446 | 0.480 |
Why?
| | Diffusion of Innovation | 1 | 2017 | 95 | 0.480 |
Why?
| | Receptors, Adrenergic, beta | 1 | 2016 | 58 | 0.470 |
Why?
| | Calcium Channels, L-Type | 1 | 2017 | 118 | 0.470 |
Why?
| | Retrospective Studies | 13 | 2026 | 17149 | 0.460 |
Why?
| | Insulin, Regular, Human | 3 | 2024 | 47 | 0.450 |
Why?
| | Body Mass Index | 8 | 2025 | 2419 | 0.450 |
Why?
| | Ambulatory Care Facilities | 2 | 2023 | 267 | 0.450 |
Why?
| | Vitamins | 1 | 2016 | 176 | 0.450 |
Why?
| | United States | 18 | 2026 | 16018 | 0.450 |
Why?
| | Myocytes, Cardiac | 1 | 2020 | 538 | 0.440 |
Why?
| | Insulin Detemir | 5 | 2017 | 8 | 0.440 |
Why?
| | Gene Expression | 1 | 2020 | 1476 | 0.440 |
Why?
| | Rats | 7 | 2020 | 5570 | 0.420 |
Why?
| | Biomarkers | 12 | 2025 | 4261 | 0.420 |
Why?
| | Drug Delivery Systems | 2 | 2018 | 380 | 0.420 |
Why?
| | Prospective Studies | 14 | 2025 | 7994 | 0.420 |
Why?
| | Drug Administration Schedule | 8 | 2017 | 779 | 0.420 |
Why?
| | Withania | 1 | 2013 | 5 | 0.410 |
Why?
| | Receptors, Adrenergic, alpha-1 | 1 | 2013 | 45 | 0.400 |
Why?
| | Glucagon | 2 | 2022 | 114 | 0.400 |
Why?
| | Antiviral Agents | 1 | 2019 | 765 | 0.400 |
Why?
| | Extracellular Fluid | 1 | 2013 | 38 | 0.390 |
Why?
| | Glucosides | 3 | 2019 | 55 | 0.390 |
Why?
| | Chlorpyrifos | 1 | 2013 | 7 | 0.380 |
Why?
| | Nervous System Diseases | 1 | 2016 | 285 | 0.380 |
Why?
| | Benzhydryl Compounds | 3 | 2019 | 81 | 0.380 |
Why?
| | History, 21st Century | 3 | 2020 | 220 | 0.380 |
Why?
| | Membrane Potential, Mitochondrial | 3 | 2024 | 74 | 0.380 |
Why?
| | Microsomes, Liver | 1 | 2013 | 85 | 0.370 |
Why?
| | Portal Vein | 1 | 2013 | 114 | 0.370 |
Why?
| | Arsenic | 1 | 2013 | 65 | 0.360 |
Why?
| | Time Factors | 12 | 2021 | 7140 | 0.360 |
Why?
| | Myocardial Infarction | 1 | 2020 | 1209 | 0.360 |
Why?
| | Pyrazines | 1 | 2013 | 92 | 0.360 |
Why?
| | Tocolytic Agents | 2 | 2017 | 16 | 0.350 |
Why?
| | Ascorbic Acid | 1 | 2013 | 171 | 0.340 |
Why?
| | Needles | 1 | 2011 | 62 | 0.340 |
Why?
| | Pregnancy Outcome | 3 | 2023 | 479 | 0.340 |
Why?
| | Triazoles | 1 | 2013 | 184 | 0.340 |
Why?
| | Adrenergic beta-Agonists | 2 | 2017 | 92 | 0.340 |
Why?
| | Patient Preference | 1 | 2013 | 226 | 0.330 |
Why?
| | Goats | 2 | 2021 | 18 | 0.330 |
Why?
| | Prevalence | 8 | 2020 | 2839 | 0.330 |
Why?
| | Clinical Trials as Topic | 7 | 2022 | 1056 | 0.320 |
Why?
| | History, 20th Century | 3 | 2019 | 327 | 0.320 |
Why?
| | Blood Chemical Analysis | 2 | 2017 | 109 | 0.310 |
Why?
| | Acetylcholine | 3 | 2019 | 208 | 0.300 |
Why?
| | Nitric Oxide Synthase Type II | 2 | 2022 | 161 | 0.300 |
Why?
| | Calibration | 3 | 2018 | 151 | 0.300 |
Why?
| | Water Pollutants, Chemical | 1 | 2013 | 229 | 0.300 |
Why?
| | DNA Damage | 2 | 2024 | 430 | 0.300 |
Why?
| | Pregnancy Trimester, First | 3 | 2020 | 136 | 0.300 |
Why?
| | Organometallic Compounds | 2 | 2024 | 113 | 0.290 |
Why?
| | China | 4 | 2020 | 269 | 0.290 |
Why?
| | Intention to Treat Analysis | 3 | 2017 | 79 | 0.290 |
Why?
| | 4-Aminopyridine | 2 | 2020 | 30 | 0.290 |
Why?
| | Health Care Costs | 4 | 2016 | 425 | 0.290 |
Why?
| | Reference Values | 6 | 2023 | 794 | 0.290 |
Why?
| | Child | 14 | 2026 | 22600 | 0.280 |
Why?
| | Plant Leaves | 3 | 2019 | 138 | 0.280 |
Why?
| | Research Design | 6 | 2015 | 1129 | 0.280 |
Why?
| | alpha-Tocopherol | 2 | 2020 | 32 | 0.280 |
Why?
| | Prediabetic State | 1 | 2011 | 247 | 0.280 |
Why?
| | Computer Systems | 2 | 2018 | 55 | 0.270 |
Why?
| | Blood Pressure | 4 | 2025 | 1766 | 0.270 |
Why?
| | Animals, Newborn | 2 | 2020 | 890 | 0.260 |
Why?
| | Veratridine | 2 | 2017 | 5 | 0.260 |
Why?
| | Longitudinal Studies | 7 | 2026 | 2942 | 0.260 |
Why?
| | Software | 3 | 2013 | 695 | 0.250 |
Why?
| | Sodium-Glucose Transport Proteins | 2 | 2017 | 3 | 0.250 |
Why?
| | Equipment Design | 4 | 2010 | 527 | 0.250 |
Why?
| | Anti-Bacterial Agents | 1 | 2017 | 1928 | 0.250 |
Why?
| | Nitric Oxide | 3 | 2022 | 894 | 0.250 |
Why?
| | United States Food and Drug Administration | 3 | 2018 | 205 | 0.240 |
Why?
| | Case-Control Studies | 3 | 2026 | 3603 | 0.240 |
Why?
| | Vasodilator Agents | 2 | 2019 | 329 | 0.240 |
Why?
| | Journal Impact Factor | 2 | 2020 | 29 | 0.240 |
Why?
| | Autoantibodies | 3 | 2026 | 1505 | 0.240 |
Why?
| | Hypertension | 4 | 2011 | 1262 | 0.230 |
Why?
| | Blotting, Western | 3 | 2017 | 1161 | 0.230 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2021 | 1207 | 0.230 |
Why?
| | Risk Factors | 8 | 2024 | 10796 | 0.230 |
Why?
| | Ruthenium Red | 2 | 2016 | 7 | 0.230 |
Why?
| | Albuminuria | 3 | 2017 | 190 | 0.230 |
Why?
| | Diabetic Retinopathy | 2 | 2005 | 199 | 0.230 |
Why?
| | Tissue Culture Techniques | 2 | 2017 | 82 | 0.220 |
Why?
| | Aged, 80 and over | 5 | 2026 | 8284 | 0.220 |
Why?
| | Copper | 2 | 2016 | 113 | 0.220 |
Why?
| | Phenylephrine | 2 | 2016 | 74 | 0.220 |
Why?
| | Lipoproteins | 2 | 2019 | 165 | 0.220 |
Why?
| | Large-Conductance Calcium-Activated Potassium Channels | 2 | 2017 | 11 | 0.220 |
Why?
| | Fasting | 1 | 2006 | 275 | 0.220 |
Why?
| | Body Weight | 7 | 2020 | 968 | 0.220 |
Why?
| | Glomerular Filtration Rate | 3 | 2025 | 764 | 0.220 |
Why?
| | Algorithms | 5 | 2018 | 1844 | 0.210 |
Why?
| | Calcinosis | 4 | 2010 | 234 | 0.210 |
Why?
| | Semen Analysis | 1 | 2024 | 14 | 0.210 |
Why?
| | Adrenergic beta-2 Receptor Agonists | 1 | 2004 | 26 | 0.210 |
Why?
| | Exercise | 2 | 2014 | 2183 | 0.210 |
Why?
| | Phosphorylation | 2 | 2020 | 1704 | 0.210 |
Why?
| | Gastric Inhibitory Polypeptide | 1 | 2024 | 13 | 0.210 |
Why?
| | Glucagon-Like Peptide-2 Receptor | 1 | 2024 | 16 | 0.210 |
Why?
| | Cyclic AMP | 1 | 2024 | 205 | 0.200 |
Why?
| | Drug Approval | 1 | 2024 | 91 | 0.200 |
Why?
| | Pyrazoles | 2 | 2018 | 512 | 0.200 |
Why?
| | Uridine Diphosphate | 1 | 2023 | 4 | 0.200 |
Why?
| | Isothiocyanates | 1 | 2023 | 3 | 0.200 |
Why?
| | Thiourea | 1 | 2023 | 41 | 0.200 |
Why?
| | Reproduction | 1 | 2025 | 207 | 0.190 |
Why?
| | Equipment Failure | 2 | 2018 | 115 | 0.190 |
Why?
| | Phthalimides | 2 | 2020 | 2 | 0.190 |
Why?
| | Dietary Supplements | 2 | 2018 | 575 | 0.190 |
Why?
| | Mass Screening | 1 | 2011 | 1348 | 0.190 |
Why?
| | Receptors, Glucagon | 1 | 2022 | 26 | 0.190 |
Why?
| | Endocrinology | 2 | 2016 | 77 | 0.180 |
Why?
| | Vitamin D-Binding Protein | 2 | 2020 | 15 | 0.180 |
Why?
| | Safety | 3 | 2009 | 356 | 0.180 |
Why?
| | Child, Preschool | 6 | 2025 | 11790 | 0.180 |
Why?
| | Ketosis | 1 | 2021 | 12 | 0.170 |
Why?
| | Reference Standards | 4 | 2017 | 178 | 0.170 |
Why?
| | Randomized Controlled Trials as Topic | 5 | 2021 | 1742 | 0.170 |
Why?
| | Mice | 5 | 2023 | 18261 | 0.170 |
Why?
| | Testis | 2 | 2025 | 162 | 0.170 |
Why?
| | Fluorocarbons | 2 | 2020 | 119 | 0.170 |
Why?
| | Mobile Applications | 2 | 2021 | 197 | 0.170 |
Why?
| | Illinois | 1 | 2021 | 49 | 0.170 |
Why?
| | Immunization, Passive | 1 | 2021 | 88 | 0.170 |
Why?
| | Patient Isolation | 1 | 2021 | 20 | 0.170 |
Why?
| | New York City | 1 | 2021 | 89 | 0.170 |
Why?
| | Los Angeles | 1 | 2021 | 76 | 0.170 |
Why?
| | Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2020 | 49 | 0.160 |
Why?
| | Progesterone | 2 | 2019 | 209 | 0.160 |
Why?
| | Micronucleus Tests | 1 | 2020 | 6 | 0.160 |
Why?
| | Comet Assay | 1 | 2020 | 14 | 0.160 |
Why?
| | Antigens, Viral | 1 | 2021 | 182 | 0.160 |
Why?
| | Interleukin-13 | 1 | 2021 | 144 | 0.160 |
Why?
| | Skin Diseases, Parasitic | 1 | 2020 | 3 | 0.160 |
Why?
| | Patient Satisfaction | 3 | 2015 | 707 | 0.160 |
Why?
| | Environmental Exposure | 1 | 2025 | 574 | 0.160 |
Why?
| | Uncoupling Protein 2 | 1 | 2020 | 9 | 0.160 |
Why?
| | Chromium | 1 | 2020 | 16 | 0.160 |
Why?
| | Practice Guidelines as Topic | 3 | 2019 | 1569 | 0.150 |
Why?
| | Cardiotoxicity | 1 | 2020 | 34 | 0.150 |
Why?
| | Incidence | 3 | 2017 | 2892 | 0.150 |
Why?
| | Intermediate-Conductance Calcium-Activated Potassium Channels | 1 | 2019 | 1 | 0.150 |
Why?
| | Curcumin | 1 | 2020 | 27 | 0.150 |
Why?
| | Income | 1 | 2021 | 201 | 0.150 |
Why?
| | Glycemic Index | 2 | 2009 | 26 | 0.150 |
Why?
| | Islets of Langerhans | 1 | 2026 | 842 | 0.150 |
Why?
| | Cyclooxygenase 1 | 1 | 2019 | 27 | 0.150 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2020 | 176 | 0.150 |
Why?
| | Vero Cells | 1 | 2019 | 84 | 0.150 |
Why?
| | Disease Models, Animal | 2 | 2020 | 4539 | 0.150 |
Why?
| | Small-Conductance Calcium-Activated Potassium Channels | 1 | 2019 | 13 | 0.150 |
Why?
| | Lipid Peroxidation | 1 | 2020 | 163 | 0.150 |
Why?
| | Virus Internalization | 1 | 2019 | 65 | 0.150 |
Why?
| | Diabetes, Gestational | 1 | 2023 | 303 | 0.150 |
Why?
| | Tyrosine | 1 | 2020 | 219 | 0.150 |
Why?
| | Host-Parasite Interactions | 1 | 2020 | 112 | 0.150 |
Why?
| | Canagliflozin | 1 | 2019 | 10 | 0.150 |
Why?
| | Haptoglobins | 1 | 2019 | 66 | 0.150 |
Why?
| | Immunity, Cellular | 2 | 2018 | 272 | 0.150 |
Why?
| | Area Under Curve | 3 | 2015 | 329 | 0.150 |
Why?
| | Adamantane | 1 | 2019 | 18 | 0.140 |
Why?
| | Liver Cirrhosis | 1 | 2021 | 287 | 0.140 |
Why?
| | Dipeptides | 1 | 2019 | 56 | 0.140 |
Why?
| | Ion Channels | 1 | 2019 | 129 | 0.140 |
Why?
| | TRPV Cation Channels | 1 | 2019 | 43 | 0.140 |
Why?
| | Congresses as Topic | 2 | 2020 | 221 | 0.140 |
Why?
| | Vitamin D | 2 | 2020 | 400 | 0.140 |
Why?
| | California | 1 | 2020 | 471 | 0.140 |
Why?
| | Meals | 1 | 2020 | 128 | 0.140 |
Why?
| | Methyldopa | 1 | 2018 | 6 | 0.140 |
Why?
| | Receptor, Cannabinoid, CB1 | 1 | 2018 | 39 | 0.140 |
Why?
| | Organ Culture Techniques | 1 | 2018 | 149 | 0.140 |
Why?
| | Self Efficacy | 1 | 2002 | 409 | 0.140 |
Why?
| | Aminooxyacetic Acid | 1 | 2017 | 1 | 0.140 |
Why?
| | Sodium Channel Agonists | 1 | 2017 | 1 | 0.140 |
Why?
| | Receptors, Adrenergic, beta-3 | 1 | 2017 | 5 | 0.140 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2020 | 550 | 0.130 |
Why?
| | Sensitivity and Specificity | 4 | 2009 | 1995 | 0.130 |
Why?
| | International Agencies | 1 | 2017 | 30 | 0.130 |
Why?
| | Analysis of Variance | 1 | 2020 | 1301 | 0.130 |
Why?
| | Hemoglobin A | 1 | 2017 | 21 | 0.130 |
Why?
| | Injections | 1 | 2018 | 197 | 0.130 |
Why?
| | Malondialdehyde | 1 | 2017 | 30 | 0.130 |
Why?
| | Serum Amyloid A Protein | 1 | 2017 | 32 | 0.130 |
Why?
| | Patient Care Planning | 1 | 2019 | 170 | 0.130 |
Why?
| | Sodium Bicarbonate | 1 | 2018 | 47 | 0.130 |
Why?
| | Glyburide | 1 | 2017 | 31 | 0.130 |
Why?
| | Propanolamines | 1 | 2017 | 40 | 0.130 |
Why?
| | Equivalence Trials as Topic | 1 | 2017 | 36 | 0.130 |
Why?
| | Administration, Oral | 2 | 2017 | 851 | 0.130 |
Why?
| | Least-Squares Analysis | 1 | 2017 | 74 | 0.130 |
Why?
| | Methanol | 1 | 2017 | 45 | 0.130 |
Why?
| | Immunization | 1 | 2019 | 374 | 0.130 |
Why?
| | Alkynes | 1 | 2017 | 66 | 0.130 |
Why?
| | Toll-Like Receptor 9 | 1 | 2017 | 37 | 0.130 |
Why?
| | HLA-DQ Antigens | 1 | 2018 | 173 | 0.130 |
Why?
| | Protein Carbonylation | 1 | 2017 | 57 | 0.130 |
Why?
| | Data Interpretation, Statistical | 1 | 2019 | 368 | 0.130 |
Why?
| | Solvents | 1 | 2017 | 113 | 0.130 |
Why?
| | Phytotherapy | 1 | 2017 | 74 | 0.130 |
Why?
| | Biomechanical Phenomena | 1 | 2021 | 852 | 0.130 |
Why?
| | Adipokines | 1 | 2017 | 57 | 0.130 |
Why?
| | Islet Amyloid Polypeptide | 3 | 2013 | 48 | 0.130 |
Why?
| | Patient Dropouts | 1 | 2017 | 65 | 0.130 |
Why?
| | Patient Compliance | 2 | 2013 | 587 | 0.130 |
Why?
| | Cyclooxygenase 2 | 1 | 2017 | 166 | 0.130 |
Why?
| | Anniversaries and Special Events | 1 | 2017 | 16 | 0.130 |
Why?
| | Fatty Acids, Nonesterified | 1 | 2017 | 154 | 0.130 |
Why?
| | Antibodies, Viral | 1 | 2021 | 672 | 0.130 |
Why?
| | Computer-Aided Design | 1 | 2017 | 40 | 0.130 |
Why?
| | Antigen Presentation | 1 | 2018 | 206 | 0.120 |
Why?
| | Uric Acid | 1 | 2018 | 166 | 0.120 |
Why?
| | Cell Survival | 1 | 2020 | 1092 | 0.120 |
Why?
| | Furans | 1 | 2016 | 27 | 0.120 |
Why?
| | Up-Regulation | 1 | 2020 | 848 | 0.120 |
Why?
| | In Vitro Techniques | 2 | 2016 | 1046 | 0.120 |
Why?
| | Clinical Protocols | 1 | 2018 | 282 | 0.120 |
Why?
| | Indicators and Reagents | 1 | 2016 | 106 | 0.120 |
Why?
| | Antibody Formation | 1 | 2018 | 291 | 0.120 |
Why?
| | Sympathomimetics | 1 | 2016 | 19 | 0.120 |
Why?
| | Oleaceae | 1 | 2016 | 1 | 0.120 |
Why?
| | Piperidines | 1 | 2018 | 219 | 0.120 |
Why?
| | Combined Modality Therapy | 2 | 2017 | 1268 | 0.120 |
Why?
| | Coronary Artery Disease | 3 | 2010 | 743 | 0.120 |
Why?
| | Glycine | 1 | 2017 | 186 | 0.120 |
Why?
| | Cysteine | 1 | 2017 | 207 | 0.120 |
Why?
| | Antihypertensive Agents | 3 | 2012 | 512 | 0.120 |
Why?
| | Socioeconomic Factors | 1 | 2021 | 1322 | 0.120 |
Why?
| | Eating | 3 | 2009 | 388 | 0.120 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2022 | 990 | 0.120 |
Why?
| | Anti-Inflammatory Agents | 1 | 2020 | 477 | 0.120 |
Why?
| | Drug Hypersensitivity | 1 | 2017 | 89 | 0.120 |
Why?
| | Comorbidity | 1 | 2021 | 1652 | 0.120 |
Why?
| | Lung | 1 | 2009 | 4089 | 0.120 |
Why?
| | Amyloid | 2 | 2007 | 90 | 0.120 |
Why?
| | Leptin | 2 | 2017 | 247 | 0.120 |
Why?
| | Membrane Potentials | 1 | 2016 | 278 | 0.120 |
Why?
| | Aniline Compounds | 1 | 2016 | 121 | 0.120 |
Why?
| | Forecasting | 2 | 2016 | 391 | 0.120 |
Why?
| | Estradiol | 1 | 2019 | 507 | 0.120 |
Why?
| | Drug Design | 1 | 2017 | 176 | 0.120 |
Why?
| | Moringa oleifera | 1 | 2015 | 3 | 0.120 |
Why?
| | Pilot Projects | 2 | 2018 | 1886 | 0.120 |
Why?
| | Vascular Stiffness | 1 | 2021 | 485 | 0.110 |
Why?
| | Interleukin-10 | 1 | 2017 | 310 | 0.110 |
Why?
| | Incretins | 1 | 2015 | 21 | 0.110 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2016 | 268 | 0.110 |
Why?
| | Toll-Like Receptor 4 | 1 | 2017 | 277 | 0.110 |
Why?
| | Imidazoles | 1 | 2016 | 246 | 0.110 |
Why?
| | Postnatal Care | 1 | 2016 | 76 | 0.110 |
Why?
| | Cells, Cultured | 2 | 2020 | 4110 | 0.110 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 2 | 2013 | 253 | 0.110 |
Why?
| | RNA, Messenger | 1 | 2023 | 2815 | 0.110 |
Why?
| | Early Diagnosis | 2 | 2015 | 249 | 0.110 |
Why?
| | Disease Management | 1 | 2019 | 650 | 0.110 |
Why?
| | Materials Testing | 2 | 2017 | 349 | 0.110 |
Why?
| | Cholesterol, HDL | 1 | 2015 | 199 | 0.100 |
Why?
| | Estrenes | 1 | 2014 | 13 | 0.100 |
Why?
| | Vitamin D Deficiency | 2 | 2020 | 187 | 0.100 |
Why?
| | Pyrrolidinones | 1 | 2014 | 29 | 0.100 |
Why?
| | Colesevelam Hydrochloride | 1 | 2013 | 6 | 0.100 |
Why?
| | Gastrins | 1 | 2013 | 8 | 0.100 |
Why?
| | Allylamine | 1 | 2013 | 6 | 0.100 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2014 | 72 | 0.100 |
Why?
| | Self-Management | 1 | 2017 | 201 | 0.100 |
Why?
| | Bromocriptine | 1 | 2013 | 31 | 0.100 |
Why?
| | Colorado | 2 | 2020 | 4558 | 0.100 |
Why?
| | Sodium-Glucose Transporter 2 | 1 | 2013 | 29 | 0.100 |
Why?
| | Immunohistochemistry | 1 | 2017 | 1705 | 0.100 |
Why?
| | Catecholamines | 1 | 2013 | 87 | 0.100 |
Why?
| | Prenatal Care | 1 | 2016 | 306 | 0.100 |
Why?
| | Staining and Labeling | 1 | 2014 | 153 | 0.100 |
Why?
| | Kidney Diseases | 1 | 2017 | 427 | 0.100 |
Why?
| | Inflammation | 1 | 2005 | 2870 | 0.100 |
Why?
| | Staphylococcus aureus | 1 | 2017 | 454 | 0.100 |
Why?
| | Toxicity Tests, Subacute | 1 | 2013 | 1 | 0.100 |
Why?
| | Enzyme Inhibitors | 1 | 2016 | 820 | 0.100 |
Why?
| | Chemistry, Pharmaceutical | 1 | 2013 | 112 | 0.100 |
Why?
| | Coronary Disease | 2 | 2007 | 381 | 0.100 |
Why?
| | Age Factors | 2 | 2019 | 3329 | 0.100 |
Why?
| | Immunologic Factors | 1 | 2015 | 259 | 0.100 |
Why?
| | Escherichia coli | 1 | 2017 | 854 | 0.100 |
Why?
| | Age of Onset | 2 | 2026 | 551 | 0.090 |
Why?
| | Sitagliptin Phosphate | 1 | 2013 | 31 | 0.090 |
Why?
| | Cooperative Behavior | 1 | 2016 | 464 | 0.090 |
Why?
| | Menopause | 1 | 2016 | 319 | 0.090 |
Why?
| | Thiazolidinediones | 1 | 2013 | 139 | 0.090 |
Why?
| | Oxidation-Reduction | 1 | 2016 | 1078 | 0.090 |
Why?
| | Delayed-Action Preparations | 1 | 2013 | 184 | 0.090 |
Why?
| | Insecticides | 1 | 2013 | 42 | 0.090 |
Why?
| | Leadership | 1 | 2017 | 400 | 0.090 |
Why?
| | T-Lymphocytes | 2 | 2018 | 1984 | 0.090 |
Why?
| | Islets of Langerhans Transplantation | 1 | 2013 | 67 | 0.090 |
Why?
| | Patient Selection | 2 | 2009 | 727 | 0.090 |
Why?
| | Quality of Life | 5 | 2016 | 3183 | 0.090 |
Why?
| | Cross-Sectional Studies | 5 | 2025 | 5870 | 0.090 |
Why?
| | Gene Expression Regulation | 2 | 2019 | 2591 | 0.090 |
Why?
| | Zinc | 1 | 2015 | 295 | 0.090 |
Why?
| | Cell Proliferation | 2 | 2016 | 2489 | 0.090 |
Why?
| | Circadian Rhythm | 4 | 2015 | 510 | 0.090 |
Why?
| | Drinking Water | 1 | 2013 | 91 | 0.090 |
Why?
| | Self Administration | 1 | 2011 | 124 | 0.080 |
Why?
| | Carotenoids | 1 | 2011 | 48 | 0.080 |
Why?
| | Internet | 1 | 2016 | 698 | 0.080 |
Why?
| | Managed Care Programs | 1 | 2011 | 140 | 0.080 |
Why?
| | Swine | 1 | 2013 | 828 | 0.080 |
Why?
| | Cohort Studies | 4 | 2019 | 5957 | 0.080 |
Why?
| | Regression Analysis | 2 | 2010 | 998 | 0.080 |
Why?
| | Eicosapentaenoic Acid | 1 | 2010 | 36 | 0.080 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 338 | 0.080 |
Why?
| | Metformin | 1 | 2013 | 320 | 0.080 |
Why?
| | Home Care Services | 1 | 2013 | 280 | 0.080 |
Why?
| | Surveys and Questionnaires | 4 | 2014 | 6041 | 0.070 |
Why?
| | Drug Combinations | 1 | 2010 | 393 | 0.070 |
Why?
| | Carcinogens | 1 | 2009 | 123 | 0.070 |
Why?
| | Decision Making | 2 | 2013 | 973 | 0.070 |
Why?
| | Physicians | 2 | 2017 | 949 | 0.070 |
Why?
| | Vital Capacity | 1 | 2009 | 290 | 0.070 |
Why?
| | Disease Progression | 3 | 2012 | 2847 | 0.070 |
Why?
| | Forced Expiratory Volume | 1 | 2009 | 448 | 0.070 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 2 | 2018 | 41 | 0.070 |
Why?
| | Immunosuppressive Agents | 1 | 2013 | 834 | 0.070 |
Why?
| | Rats, Sprague-Dawley | 1 | 2013 | 2521 | 0.070 |
Why?
| | C-Reactive Protein | 2 | 2013 | 420 | 0.070 |
Why?
| | Angiotensin II Type 2 Receptor Blockers | 1 | 2007 | 7 | 0.070 |
Why?
| | Norway | 2 | 2019 | 41 | 0.070 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2007 | 76 | 0.060 |
Why?
| | Drug Costs | 1 | 2008 | 117 | 0.060 |
Why?
| | Sheep | 1 | 2010 | 880 | 0.060 |
Why?
| | Medication Adherence | 1 | 2011 | 540 | 0.060 |
Why?
| | Nebulizers and Vaporizers | 1 | 2007 | 62 | 0.060 |
Why?
| | Infusion Pumps, Implantable | 2 | 2004 | 27 | 0.060 |
Why?
| | Risk Management | 2 | 2019 | 83 | 0.060 |
Why?
| | Renin-Angiotensin System | 1 | 2007 | 79 | 0.060 |
Why?
| | Australia | 2 | 2019 | 287 | 0.060 |
Why?
| | Zinc Transporter 8 | 1 | 2026 | 70 | 0.060 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2007 | 228 | 0.060 |
Why?
| | Societies, Medical | 1 | 2010 | 890 | 0.060 |
Why?
| | Creatinine | 2 | 2018 | 509 | 0.060 |
Why?
| | Infant | 1 | 2020 | 10023 | 0.060 |
Why?
| | Alprostadil | 1 | 2005 | 29 | 0.060 |
Why?
| | Immunity, Humoral | 2 | 2016 | 120 | 0.050 |
Why?
| | Patient Acceptance of Health Care | 1 | 2012 | 881 | 0.050 |
Why?
| | Attitude of Health Personnel | 1 | 2013 | 1180 | 0.050 |
Why?
| | Barium Compounds | 1 | 2004 | 12 | 0.050 |
Why?
| | Terbutaline | 1 | 2004 | 7 | 0.050 |
Why?
| | Organ Size | 2 | 2016 | 461 | 0.050 |
Why?
| | Potassium Chloride | 1 | 2004 | 40 | 0.050 |
Why?
| | Abortifacient Agents, Nonsteroidal | 1 | 2004 | 19 | 0.050 |
Why?
| | Spermatogenesis | 1 | 2025 | 91 | 0.050 |
Why?
| | Receptors, Adrenergic, beta-2 | 1 | 2004 | 36 | 0.050 |
Why?
| | Dinoprostone | 1 | 2005 | 180 | 0.050 |
Why?
| | Albuterol | 1 | 2004 | 73 | 0.050 |
Why?
| | Hyperlipidemias | 1 | 2005 | 120 | 0.050 |
Why?
| | Automation | 1 | 2004 | 104 | 0.050 |
Why?
| | Pulmonary Artery | 1 | 2010 | 1124 | 0.050 |
Why?
| | Chlorides | 1 | 2004 | 142 | 0.050 |
Why?
| | Modems | 1 | 2003 | 1 | 0.050 |
Why?
| | Capillaries | 1 | 2004 | 118 | 0.050 |
Why?
| | Homeostasis | 1 | 2007 | 639 | 0.050 |
Why?
| | Propensity Score | 1 | 2025 | 373 | 0.050 |
Why?
| | Glycation End Products, Advanced | 1 | 2023 | 41 | 0.050 |
Why?
| | Food | 1 | 2004 | 148 | 0.050 |
Why?
| | Fetal Macrosomia | 1 | 2003 | 62 | 0.050 |
Why?
| | Transaminases | 1 | 2022 | 22 | 0.050 |
Why?
| | Primary Health Care | 1 | 2013 | 1730 | 0.050 |
Why?
| | Costs and Cost Analysis | 1 | 2003 | 221 | 0.050 |
Why?
| | Congenital Abnormalities | 1 | 2003 | 104 | 0.050 |
Why?
| | Educational Status | 1 | 2004 | 463 | 0.040 |
Why?
| | Lipoproteins, LDL | 1 | 2022 | 119 | 0.040 |
Why?
| | Ketone Bodies | 1 | 2021 | 15 | 0.040 |
Why?
| | Preconception Care | 1 | 2002 | 49 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2020 | 5414 | 0.040 |
Why?
| | Labor, Obstetric | 1 | 2002 | 67 | 0.040 |
Why?
| | Breath Tests | 1 | 2021 | 77 | 0.040 |
Why?
| | Brain | 1 | 2013 | 2934 | 0.040 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2005 | 438 | 0.040 |
Why?
| | Prognosis | 2 | 2020 | 4312 | 0.040 |
Why?
| | Ketones | 1 | 2021 | 53 | 0.040 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2021 | 116 | 0.040 |
Why?
| | Pregnancy Trimester, Second | 1 | 2020 | 80 | 0.040 |
Why?
| | Learning | 1 | 2004 | 448 | 0.040 |
Why?
| | Birth Weight | 1 | 2003 | 506 | 0.040 |
Why?
| | Self Concept | 1 | 2002 | 256 | 0.040 |
Why?
| | Immunoglobulin Fc Fragments | 1 | 2020 | 41 | 0.040 |
Why?
| | Gestational Age | 1 | 2003 | 980 | 0.040 |
Why?
| | Vascular Resistance | 1 | 2021 | 368 | 0.040 |
Why?
| | Skin | 1 | 2004 | 762 | 0.040 |
Why?
| | Polyunsaturated Alkamides | 1 | 2019 | 8 | 0.040 |
Why?
| | Capsaicin | 1 | 2019 | 30 | 0.040 |
Why?
| | Immunoblotting | 1 | 2019 | 293 | 0.040 |
Why?
| | Arachidonic Acids | 1 | 2019 | 43 | 0.040 |
Why?
| | Data Accuracy | 1 | 2019 | 65 | 0.040 |
Why?
| | Postpartum Period | 1 | 2002 | 368 | 0.040 |
Why?
| | Databases, Factual | 1 | 2004 | 1494 | 0.030 |
Why?
| | Internationality | 1 | 2019 | 154 | 0.030 |
Why?
| | Microscopy, Polarization | 1 | 2018 | 30 | 0.030 |
Why?
| | Osmolar Concentration | 1 | 2018 | 169 | 0.030 |
Why?
| | Sodium | 1 | 2019 | 198 | 0.030 |
Why?
| | Retinol-Binding Proteins, Plasma | 1 | 2017 | 6 | 0.030 |
Why?
| | Resistin | 1 | 2017 | 12 | 0.030 |
Why?
| | Lipocalin-2 | 1 | 2017 | 80 | 0.030 |
Why?
| | North America | 1 | 2018 | 312 | 0.030 |
Why?
| | Multicenter Studies as Topic | 1 | 2019 | 408 | 0.030 |
Why?
| | Lost to Follow-Up | 1 | 2017 | 20 | 0.030 |
Why?
| | Survival Rate | 1 | 2022 | 2089 | 0.030 |
Why?
| | Recombinant Fusion Proteins | 1 | 2020 | 667 | 0.030 |
Why?
| | Fatty Acid-Binding Proteins | 1 | 2017 | 79 | 0.030 |
Why?
| | Seminiferous Tubules | 1 | 2016 | 13 | 0.030 |
Why?
| | Sleep | 2 | 2015 | 890 | 0.030 |
Why?
| | Semen | 1 | 2016 | 24 | 0.030 |
Why?
| | Hypersensitivity, Delayed | 1 | 2016 | 29 | 0.030 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2018 | 562 | 0.030 |
Why?
| | Drug Resistance | 1 | 2017 | 145 | 0.030 |
Why?
| | Mice, Inbred NOD | 1 | 2018 | 610 | 0.030 |
Why?
| | Polymorphism, Genetic | 2 | 2010 | 613 | 0.030 |
Why?
| | Cost Savings | 1 | 2016 | 85 | 0.030 |
Why?
| | Edema | 1 | 2016 | 124 | 0.030 |
Why?
| | Models, Economic | 1 | 2016 | 61 | 0.030 |
Why?
| | Research Personnel | 1 | 2017 | 185 | 0.030 |
Why?
| | Adiponectin | 1 | 2017 | 240 | 0.030 |
Why?
| | Antibodies, Bacterial | 1 | 2016 | 146 | 0.030 |
Why?
| | Equipment and Supplies | 1 | 2015 | 35 | 0.030 |
Why?
| | Kidney | 1 | 2023 | 1495 | 0.030 |
Why?
| | Physician-Patient Relations | 1 | 2020 | 589 | 0.030 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2015 | 127 | 0.030 |
Why?
| | Flowers | 1 | 2016 | 70 | 0.030 |
Why?
| | Body Burden | 1 | 2015 | 7 | 0.030 |
Why?
| | Interleukin-2 | 1 | 2016 | 438 | 0.030 |
Why?
| | C-Peptide | 1 | 2015 | 190 | 0.030 |
Why?
| | Salmonella typhimurium | 1 | 2016 | 189 | 0.030 |
Why?
| | Consensus | 1 | 2016 | 475 | 0.030 |
Why?
| | Communication | 1 | 2020 | 972 | 0.030 |
Why?
| | Genotype | 2 | 2010 | 1847 | 0.030 |
Why?
| | Neoplasms | 1 | 2009 | 2873 | 0.030 |
Why?
| | Academic Medical Centers | 1 | 2017 | 545 | 0.030 |
Why?
| | Drug Monitoring | 1 | 2017 | 396 | 0.020 |
Why?
| | Delivery of Health Care | 1 | 2020 | 944 | 0.020 |
Why?
| | Liver | 1 | 2022 | 1889 | 0.020 |
Why?
| | Prenatal Diagnosis | 1 | 2015 | 196 | 0.020 |
Why?
| | Activities of Daily Living | 1 | 2017 | 441 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 835 | 0.020 |
Why?
| | Cost-Benefit Analysis | 1 | 2016 | 638 | 0.020 |
Why?
| | Data Display | 1 | 2013 | 20 | 0.020 |
Why?
| | E-Selectin | 1 | 2013 | 61 | 0.020 |
Why?
| | Chemokine CXCL10 | 1 | 2013 | 39 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2018 | 2184 | 0.020 |
Why?
| | Testosterone | 1 | 2016 | 412 | 0.020 |
Why?
| | Risk | 1 | 2015 | 911 | 0.020 |
Why?
| | Electronic Health Records | 1 | 2020 | 1176 | 0.020 |
Why?
| | Statistics as Topic | 1 | 2013 | 284 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2016 | 770 | 0.020 |
Why?
| | Bone and Bones | 1 | 2015 | 317 | 0.020 |
Why?
| | Health Services Accessibility | 1 | 2020 | 1098 | 0.020 |
Why?
| | Tetraethylammonium | 1 | 2011 | 16 | 0.020 |
Why?
| | beta Carotene | 1 | 2011 | 20 | 0.020 |
Why?
| | Phenotype | 1 | 2019 | 3147 | 0.020 |
Why?
| | Vitamin A | 1 | 2011 | 59 | 0.020 |
Why?
| | Receptors, Calcitriol | 1 | 2010 | 55 | 0.020 |
Why?
| | Calcium Chloride | 1 | 2010 | 12 | 0.020 |
Why?
| | Expert Testimony | 1 | 2010 | 42 | 0.020 |
Why?
| | Serotonin Antagonists | 1 | 2010 | 30 | 0.020 |
Why?
| | Cholesterol | 1 | 2012 | 404 | 0.020 |
Why?
| | Benzimidazoles | 1 | 2011 | 187 | 0.020 |
Why?
| | Nitrites | 1 | 2010 | 89 | 0.020 |
Why?
| | Intracellular Space | 1 | 2010 | 64 | 0.020 |
Why?
| | B-Lymphocytes | 1 | 2015 | 875 | 0.020 |
Why?
| | Extracellular Space | 1 | 2010 | 119 | 0.020 |
Why?
| | Potassium | 1 | 2010 | 152 | 0.020 |
Why?
| | Nitric Oxide Synthase | 1 | 2010 | 234 | 0.020 |
Why?
| | Vasoconstrictor Agents | 1 | 2010 | 144 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 973 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2017 | 2922 | 0.020 |
Why?
| | Serotonin | 1 | 2010 | 294 | 0.020 |
Why?
| | Angiotensins | 1 | 2007 | 8 | 0.020 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2007 | 25 | 0.020 |
Why?
| | Peptidyl-Dipeptidase A | 1 | 2007 | 56 | 0.020 |
Why?
| | Insurance, Health, Reimbursement | 1 | 2007 | 97 | 0.020 |
Why?
| | Long-Term Care | 1 | 2007 | 117 | 0.020 |
Why?
| | Fatty Acids | 1 | 2010 | 454 | 0.020 |
Why?
| | Peptides | 1 | 2011 | 989 | 0.010 |
Why?
| | Models, Biological | 1 | 2013 | 1811 | 0.010 |
Why?
| | Fructosamine | 1 | 2005 | 11 | 0.010 |
Why?
| | Predictive Value of Tests | 1 | 2010 | 2117 | 0.010 |
Why?
| | Hemoglobins | 1 | 2007 | 381 | 0.010 |
Why?
| | Age Distribution | 1 | 2005 | 402 | 0.010 |
Why?
| | Sex Distribution | 1 | 2005 | 386 | 0.010 |
Why?
| | Hemoglobinuria | 1 | 2003 | 5 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 2 | 2003 | 2754 | 0.010 |
Why?
| | Logistic Models | 1 | 2003 | 2114 | 0.010 |
Why?
| | Sex Characteristics | 1 | 2003 | 776 | 0.010 |
Why?
| | Insulin Resistance | 1 | 2003 | 1241 | 0.010 |
Why?
|
|
Garg's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|